N,N′-(propane-1,3-diyl) bis(2-bromoethanamide) | 4960-83-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N,N′-(propane-1,3-diyl) bis(2-bromoethanamide)
• 英文别名: 1.3-Bis-bromacetamino-propan；N,N'-1,3-Propanediylbis[2-bromoacetamide]；2-bromo-N-[3-[(2-bromoacetyl)amino]propyl]acetamide
• CAS: 4960-83-2
• 化学式: C₇H₁₂Br₂N₂O₂
• 分子量: 315.992
• InChiKey: IEJHXBYYIGKJEF-UHFFFAOYSA-N

物化性质

• 熔点：
  106 °C
• 沸点：
  518.7±45.0 °C(Predicted)
• 密度：
  1.733±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N′-(propane-1,3-diyl) bis(2-bromoethanamide) 、 N-hexylbenzimidazole 以 乙腈 为溶剂， 生成
  参考文献：
  名称：

  直面威胁：设计高效双苯并咪唑鎓制剂以克服生物膜持久性和抗菌素耐药性

  摘要：

  这项研究的目的是采取初步措施开发新型抗生素，以解决不断升级的抗菌和细菌持久性问题，特别是与生物膜相关的问题。我们的方法涉及模拟阳离子抗菌肽的结构特征。为了避免耐药性的发展，我们设计了一个双苯并咪唑鎓盐库，它以非特异性方式选择性地靶向微生物膜。为了探索它们的结构-活性关系，我们使用这些化合物对已知对传统抗生素具有耐药性的各种病原体进行了实验，包括革兰氏阳性耐甲氧西林金黄色葡萄球菌（MRSA）、耐万古霉素屎肠球菌（VRE）和革兰氏阳性菌。阴性大肠杆菌（E. coli）。值得注意的是，与哺乳动物细胞相比，两种双苯并咪唑鎓盐表现出强大的抗菌活性，同时保持高水平的选择性。我们的研究揭示了显着的抗生物膜活性，因为这些化合物迅速对抗已形成的生物膜。此外，双苯并咪唑化合物在耐药性发展和交叉耐药性研究中表现出一致的结果。因此，两亲性双苯并咪唑鎓盐有望成为对抗耐药性相关感染的潜在候选物。

  DOI：

  10.1021/acsinfecdis.3c00289
• 作为产物：
  描述：

  溴代乙酸酐 、 1,3-丙二胺 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以53%的产率得到N,N′-(propane-1,3-diyl) bis(2-bromoethanamide)
  参考文献：
  名称：

  [EN] PEPTIDE CONJUGATES AND METHODS OF USE
  [FR] CONJUGUÉS PEPTIDIQUES ET MÉTHODES D'UTILISATION

  摘要：

  本文披露了包括以下内容的肽共轭物：选择自可调节PYY受体的肽、可调节GLP-1受体和GCG受体的肽、可调节GLP-1受体和GIP受体的肽、以及可调节GLP-1受体的肽；以及连接到肽的稳定剂，在第一个氨基酸和第二个氨基酸处连接。还提供了包括催乳素释放肽的肽共轭物。这些肽共轭物可用于治疗肥胖等疾病。此外，还提供了稳定的催乳素释放肽。

  公开号：

  WO2021113535A1

文献信息

• Selective and broad spectrum amphiphilic small molecules to combat bacterial resistance and eradicate biofilms
  作者：Jiaul Hoque、Mohini M. Konai、Sandip Samaddar、Spandhana Gonuguntala、Goutham B. Manjunath、Chandradhish Ghosh、Jayanta Haldar

  DOI：10.1039/c5cc05159b

  日期：——

  Membrane-active amphiphilic small molecules selectively kill bacteria over mammalian cells, disperse preformed biofilms and reduce bacterial resistance development.

  膜活性两性小分子选择性杀死细菌而不伤害哺乳动物细胞，分散已形成的生物膜并减少细菌的抗药性发展。
• [EN] LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE<br/>[FR] CONJUGUÉS PEPTIDIQUES DOUBLE GIP/GLP-1 À ACTION PROLONGÉE ET PROCÉDÉS D'UTILISATION
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2022257979A1

  公开（公告）日：2022-12-15

  Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

  本文提供了含有双重葡萄糖依赖性胰岛素促泌肽（GIP）和GLP-1受体激动剂的肽和肽共轭物。这些肽可以用于血糖管理和治疗糖尿病、肥胖症、非酒精性脂肪肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）等疾病。
• Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
  申请人：THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH

  公开号：US10039809B2

  公开（公告）日：2018-08-07

  Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.

  提供了延长治疗剂半衰期的方法和组合物。改性治疗剂（mTA）由治疗剂、主食和延长半衰期分子组成。本文公开的 mTA 可用于治疗有需要的受试者的疾病或病症。
• Membrane Active Small Molecules Show Selective Broad Spectrum Antibacterial Activity with No Detectable Resistance and Eradicate Biofilms
  作者：Jiaul Hoque、Mohini M. Konai、Spandhana Gonuguntla、Goutham B. Manjunath、Sandip Samaddar、Venkateswarlu Yarlagadda、Jayanta Haldar

  DOI：10.1021/acs.jmedchem.5b00443

  日期：2015.7.23

  Treating bacterial biofilms With conventional antibiotics is limited due to ineffectiveness of the drugs and higher propensity to develop bacterial resistance. Development of new classes of antibacterial therapeutics with alternative mechanisms of action has become imperative. Herein, we report the design, synthesis, and biological evaluations of novel membrane,active small molecules featuring two positive charges, four nonpeptidic,amide groups, and variable hydro, phobic/hydrophilic (amphiphilic) character. The biocides synthesized via a facile methodology not only displayed good antibacterial activity against wild-type bacteria but also showed high activity against various drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE), and beta-lactam-resistant Klebsiella pneumoniae. Further, these biocides not only inhibited the formation of biofilms but also disrupted the established S. aureus and E. coli biofilms. The membrane-active biocides hindered the propensity to develop bacterial resistance. Moreover; the biocides showed negligible toxicity against mammalian cells and thus bear potential to be used as therapeutic agents.
• Engineering of a Potent, Long-Acting NPY2R Agonist for Combination with a GLP-1R Agonist as a Multi-Hormonal Treatment for Obesity
  作者：Sam Lear、Elsa Pflimlin、Zhihong Zhou、David Huang、Sharon Weng、Van Nguyen-Tran、Sean B. Joseph、Shane Roller、Scott Peterson、Jing Li、Matthew Tremblay、Peter G. Schultz、Weijun Shen

  DOI：10.1021/acs.jmedchem.0c00740

  日期：2020.9.10

  Bariatric surgery results in increased intestinal secretion of hormones GLP-1 and anorexigenic PYY, which is believed to contribute to the clinical efficacy associated with the procedure. This observation raises the question whether combination treatment with gut hormone analogs might recapitulate the efficacy and mitigate the significant risks associated with surgery. Despite PYY demonstrating excellent efficacy and safety profiles with regard to food intake reduction, weight loss, and glucose control in preclinical animal models, PYY-based therapeutic development remains challenging given a low serum stability and half-life for the native peptide. Here, combined peptide stapling and PEG-fatty acid conjugation affords potent PYY analogs with >14 h rat half-lives, which are expected to translate into a human half-life suitable for once-weekly dosing. Excellent efficacy in glucose control, food intake reduction, and weight loss for lead candidate 22 in combination with our previously reported long-acting GLP-1 analog is demonstrated in a diet-induced obesity mouse model.